Literature DB >> 15045621

Apolipoprotein E polymorphism in patients with neuropsychiatric SLE.

Rudolf Pullmann1, Mária Skerenová, Jana Hybenová, Jozef Lukác, Jozef Rovenský, Rudolf Pullmann1.   

Abstract

The aim of this study was to investigate a relationship between neuropsychiatric SLE (NPSLE), characterized by many different neurological and psychiatric disorders, and the polymorphism of apoE as a neurobiologically important molecule conferring increased risk and a worse prognosis of a variety of CNS diseases. One hundred and forty-six SLE patients and 93 healthy controls were studied. Out of the SLE cohort, 48 patients (32.8%) were diagnosed with NPSLE and further classified according to criteria of onset, extent, relapsing tendency and type of neuropsychiatric impairment. Apolipoprotein E (apoE) polymorphism was determined by PCR-RFLP and confirmed by isoelectrofocusing. The frequency of the epsilon4 allele was significantly higher in the NPSLE group than in the non-NPSLE group (17.7% vs. 3.1%, chi(2)=19.05, p<0.0001). Distribution of apoE genotypes was significantly different between NPSLE and non-NPSLE groups (chi(2)=80.95, p<0.0001). Both epsilon4 allele frequency (17.7% vs 8.6%, chi(2)=5.082, p<0.024) and genotype distribution (chi(2)=7.202, p<0.027) were significantly different between NPSLE group and the controls. The allele epsilon4 was also associated with earlier disease onset (Fisher's test, p<0.036) and peripheral nervous system involvement (chi(2)=8.242, p<0.0041), but not with relapse frequency ( p<0.37) or major/minor subtype of the disease ( p<0.90). The epsilon4 allele carriers did not develop significantly more neuropsychiatric syndromes than non- carriers (1.75+/-0.23 sy (mean +/- SD) in epsilon4 vs 1.85+/-0.19 sy (mean +/- SD) in non-epsilon4 carriers, Mann-Whitney test, p<0.78). In conclusion, the data suggest an association between apoE polymorphism and NPSLE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15045621     DOI: 10.1007/s10067-003-0796-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

1.  Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

Authors:  M Buttini; M Orth; S Bellosta; H Akeefe; R E Pitas; T Wyss-Coray; L Mucke; R W Mahley
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.

Authors:  C C Mok; C S Lau; R W Wong
Journal:  J Rheumatol       Date:  2001-04       Impact factor: 4.666

3.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

4.  Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia.

Authors:  C R Harrington; M Roth; J H Xuereb; P J McKenna; C M Wischik
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

Review 5.  Neuropsychiatric systemic lupus erythematosus. Stress, stroke, and seizures.

Authors:  P M Moore
Journal:  Ann N Y Acad Sci       Date:  1997-08-14       Impact factor: 5.691

Review 6.  Apolipoprotein E and atherosclerosis.

Authors:  L K Curtiss; W A Boisvert
Journal:  Curr Opin Lipidol       Date:  2000-06       Impact factor: 4.776

Review 7.  Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses.

Authors:  A M Saunders
Journal:  J Neuropathol Exp Neurol       Date:  2000-09       Impact factor: 3.685

8.  Risk factors for central nervous system involvement in systemic lupus erythematosus.

Authors:  F B Karassa; J P Ioannidis; G Touloumi; K A Boki; H M Moutsopoulos
Journal:  QJM       Date:  2000-03

Review 9.  Lupus and the central nervous system.

Authors:  S G West
Journal:  Curr Opin Rheumatol       Date:  1996-09       Impact factor: 5.006

10.  Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity.

Authors:  M E Kelly; M A Clay; M J Mistry; H M Hsieh-Li; J A Harmony
Journal:  Cell Immunol       Date:  1994-12       Impact factor: 4.868

View more
  4 in total

Review 1.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

2.  Apolipoprotein E Gene Polymorphisms in Saudi Patients with Systemic Lupus Erythematosus.

Authors:  Hannan Al-Rayes; Ghaleb Huraib; Saeed Julkhuf; Misbahul Arfin; Mohammad Tariq; Abdulrahman Al-Asmari
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2016-05-22

3.  A Systems Biology-Based Investigation into the Pharmacological Mechanisms of Sheng-ma-bie-jia-tang Acting on Systemic Lupus Erythematosus by Multi-Level Data Integration.

Authors:  Lin Huang; Qi Lv; Fenfen Liu; Tieliu Shi; Chengping Wen
Journal:  Sci Rep       Date:  2015-11-12       Impact factor: 4.379

4.  A Novel Microglia-Specific Transcriptional Signature Correlates With Behavioral Deficits in Neuropsychiatric Lupus.

Authors:  Hadijat M Makinde; Deborah R Winter; Daniele Procissi; Elise V Mike; Ariel D Stock; Mary J Kando; Gaurav T Gadhvi; Steven Droho; Christina L Bloomfield; Salina T Dominguez; Maximilian G Mayr; Jeremy A Lavine; Chaim Putterman; Carla M Cuda
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.